Aberdeen Group plc Increases Position in DexCom, Inc. $DXCM

Aberdeen Group plc increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 59.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 486,373 shares of the medical device company’s stock after acquiring an additional 180,943 shares during the quarter. Aberdeen Group plc owned approximately 0.12% of DexCom worth $32,490,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Andra AP fonden acquired a new stake in shares of DexCom during the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom during the second quarter worth about $26,000. SJS Investment Consulting Inc. boosted its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. purchased a new stake in DexCom in the 3rd quarter valued at about $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom in the 2nd quarter valued at about $45,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Up 7.6%

Shares of NASDAQ DXCM opened at $70.02 on Tuesday. The stock has a fifty day moving average price of $69.12 and a 200 day moving average price of $69.39. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The company has a market cap of $26.95 billion, a P/E ratio of 33.34, a P/E/G ratio of 1.25 and a beta of 1.49.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the firm posted $0.45 earnings per share. The firm’s quarterly revenue was up 13.1% on a year-over-year basis. Research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of DexCom in a report on Tuesday, October 21st. They set a “buy” rating and a $85.00 price objective on the stock. Canaccord Genuity Group set a $95.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday. UBS Group dropped their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a report on Monday, November 3rd. TD Cowen cut their target price on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Finally, Truist Financial reissued a “buy” rating and set a $82.00 price target (down previously from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $85.27.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.